Tumor Necrosis Factor Inhibiting Agents

Tumor necrosis factor inhibiting agents, also referred to as TNF inhibitors or TNF blockers, are a therapeutic class of biologic disease-modifying antirheumatic drugs designed to suppress immune-mediated inflammation They function by binding directly to soluble and membrane-bound tumor necrosis factor-alpha or by intercepting its interaction with cell-surface receptors, thereby disrupting the downstream cytokine cascade that drives chronic inflammatory tissue damage

Tumor necrosis factor inhibiting agents, also referred to as TNF inhibitors or TNF blockers, are a therapeutic class of biologic disease-modifying antirheumatic drugs designed to suppress immune-mediated inflammation They function by binding directly to soluble and membrane-bound tumor necrosis factor-alpha or by intercepting its interaction with cell-surface receptors, thereby disrupting the downstream cytokine cascade that drives chronic inflammatory tissue damage Clinically, these agents are ...

They function by binding directly to soluble and membrane-bound tumor necrosis factor-alpha or by intercepting its interaction with cell-surface receptors, thereby disrupting the downstream cytokine cascade that drives chronic inflammatory tissue damage

Clinically, these agents are primarily indicated for chronic autoimmune and inflammatory disorders across rheumatology, gastroenterology, and dermatology, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis

Clinically, these agents are primarily indicated for chronic autoimmune and inflammatory disorders across rheumatology, gastroenterology, and dermatology, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis